share_log

S-3/A: Registration statement for specified transactions by certain issuers (Amendment)

S-3/A: Registration statement for specified transactions by certain issuers (Amendment)

S-3/A:特定交易注册声明(修正)
美股SEC公告 ·  09/19 17:05

Moomoo AI 已提取核心信息

Aclarion, Inc., a healthcare technology company specializing in Magnetic Resonance Spectroscopy (MRS) for the U.S. low back and neck pain market, has filed an amendment to its Form S-3 registration statement with the Securities and Exchange Commission (SEC) on September 19, 2024. The amendment includes details on the company's plans to offer up to $50,000,000 in securities, which may consist of common stock, preferred stock, warrants, subscription rights, debt securities, or units. The securities may be offered from time to time and in one or more series, with the specific terms to be detailed in future prospectus supplements. Aclarion's common stock is quoted on the Nasdaq Capital Market under the symbol 'ACON.' The company has faced compliance issues with Nasdaq...Show More
Aclarion, Inc., a healthcare technology company specializing in Magnetic Resonance Spectroscopy (MRS) for the U.S. low back and neck pain market, has filed an amendment to its Form S-3 registration statement with the Securities and Exchange Commission (SEC) on September 19, 2024. The amendment includes details on the company's plans to offer up to $50,000,000 in securities, which may consist of common stock, preferred stock, warrants, subscription rights, debt securities, or units. The securities may be offered from time to time and in one or more series, with the specific terms to be detailed in future prospectus supplements. Aclarion's common stock is quoted on the Nasdaq Capital Market under the symbol 'ACON.' The company has faced compliance issues with Nasdaq's minimum bid price and stockholders' equity requirements, leading to deficiency letters and an appeal hearing scheduled for October 10, 2024. Aclarion intends to take measures to regain compliance and remain listed on Nasdaq. The registration statement also includes provisions for indemnification of directors and officers, anti-takeover measures, and choice of forum clauses for legal proceedings.
Aclarion, Inc.是一家专注于美国腰背部和颈部疼痛市场的磁共振波谱技术(MRS)的医疗科技公司,于2024年9月19日向美国证券交易委员会(SEC)提交了S-3表格注册声明的修正案。修正案包括有关该公司计划发行高达5,000万美元证券的详细信息,可能包括普通股、优先股、权证、认购权、债券或单位。证券可能不时及以一种或多种系列进行发行,具体条款将在未来的招股说明书中详细说明。Aclarion的普通股在纳斯达克资本市场以'ACON'标的进行报价。该公司因纳斯达克的最低买入价和股东权益要求而面临合规问题,导致了违规通知书和定于2024年10月10日的上诉听证会。Aclarion打算采取措施恢复合规并继续在纳斯达克上市。注册声明还包括对董事和高管的赔偿条款、反收购措施以及法律诉讼的选择性司法管辖条款。
Aclarion, Inc.是一家专注于美国腰背部和颈部疼痛市场的磁共振波谱技术(MRS)的医疗科技公司,于2024年9月19日向美国证券交易委员会(SEC)提交了S-3表格注册声明的修正案。修正案包括有关该公司计划发行高达5,000万美元证券的详细信息,可能包括普通股、优先股、权证、认购权、债券或单位。证券可能不时及以一种或多种系列进行发行,具体条款将在未来的招股说明书中详细说明。Aclarion的普通股在纳斯达克资本市场以'ACON'标的进行报价。该公司因纳斯达克的最低买入价和股东权益要求而面临合规问题,导致了违规通知书和定于2024年10月10日的上诉听证会。Aclarion打算采取措施恢复合规并继续在纳斯达克上市。注册声明还包括对董事和高管的赔偿条款、反收购措施以及法律诉讼的选择性司法管辖条款。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息